Gastrointestinal Stromal Tumor Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceutical

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Gastrointestinal Stromal Tumor pipeline constitutes 25+ key companies continuously working towards developing 28+ Gastrointestinal Stromal Tumor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Gastrointestinal Stromal Tumor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastrointestinal Stromal Tumor Market.

The Gastrointestinal Stromal Tumor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Gastrointestinal Stromal Tumor Pipeline Report: https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Gastrointestinal Stromal Tumor treatment therapies with a considerable amount of success over the years.
• Gastrointestinal Stromal Tumor companies working in the treatment market are IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., Cogent Biosciences, Ascentage Pharma Group, Daiichi Sankyo Company, and others, are developing therapies for the Gastrointestinal Stromal Tumor treatment
• Emerging Gastrointestinal Stromal Tumor therapies in the different phases of clinical trials are- IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, PLX9486, Nilotinib, HQP1351, DS 6157, and others are expected to have a significant impact on the Gastrointestinal Stromal Tumor market in the coming years.
• In October 2023, Combining regorafenib with avelumab showed promising long-term advantages for certain individuals diagnosed with gastrointestinal stromal tumors (GIST).
• In June 2022, The US Food and Drug Administration (FDA) gave Immunicum AB's ilixadencel an Orphan Drug Designation (ODD) for the management of Gastrointestinal Stromal Tumours (GIST)
• In January 2022, A Phase III open-label, multinational, multicenter research of CGT9486 in conjunction with sunitinib was started by Cogent Biosciences, Inc. There will be about 426 patients enrolled in this multi-part trial.
• The selective tyrosine kinase inhibitor PLX9486 is intended to effectively inhibit D816V and other KIT exon 17 mutations. It is challenging to obtain wide therapeutic KIT inhibition since the majority of patients with imatinib-resistant GIST have both primary and secondary KIT mutations, frequently including secondary mutations on exon 17 and exon 13. In the first half of 2023, Cogent Biosciences, Inc. will present preliminary findings from PEAK, a registrational randomised, open-label, international Phase III clinical trial for patients with gastrointestinal stromal tumours (GIST)
• In June 2022, The third-generation tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351) was studied in a Phase Ib/II research in patients with metastatic gastrointestinal stromal tumours (GIST) who had either failed or been resistant to earlier TKI treatment. The results were released by Ascentage Pharma. Olverembatinib (HQP1351), according to the manufacturer, showed encouraging anticancer efficacy in patients with gastrointestinal stromal tumours (GIST) that were resistant to tyrosine kinase inhibitors (TKIs) but low in succinate dehydrogenase (SDH). Olverembatinib will be jointly developed and commercialised in the Chinese cancer market by Ascentage Pharma and Innovent Biologics (1801.HK) beginning in July 2021
• In January 2022, The lead candidate, THE-630, is being evaluated in patients with advanced gastrointestinal stromal tumours (GIST) in Theseus' current Phase I/II research, according to a statement from the company. The first data set is anticipated in 1H 2023. The company's flagship candidate THE-630 was given orphan drug designation (ODD) by the US Food and Drug Administration in February 2022 for the treatment of patients with advanced gastrointestinal stromal tumours (GIST)

Gastrointestinal Stromal Tumor Overview
A gastrointestinal stromal tumor (GIST) is a type of soft tissue sarcoma that develops in the gastrointestinal (GI) tract, which includes the stomach, small intestine, large intestine, rectm, and esophagus. GISTs typically originate from specialized cells in the wall of the GI tract called interstitial cells of Cajal (ICCs), which regulate the movement of food and fluids through the digestive system.

Get a Free Sample PDF Report to know more about Gastrointestinal Stromal Tumor Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Gastrointestinal Stromal Tumor Drugs Under Different Phases of Clinical Development Include:
• IDRX-42: IDRx, Inc
• THE-630: Theseus Pharmaceuticals
• PDR001: Novartis
• Crenolanib: Arog Pharmaceuticals, Inc.
• Famitinib: Jiangsu HengRui Medicine Co., Ltd.
• CGT9486: Cogent Biosciences, Inc.
• PLX9486: Cogent Biosciences
• Nilotinib: Novartis
• HQP1351: Ascentage Pharma Group
• DS 6157: Daiichi Sankyo Company

Gastrointestinal Stromal Tumor Route of Administration
Gastrointestinal Stromal Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Gastrointestinal Stromal Tumor Molecule Type
Gastrointestinal Stromal Tumor Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment
• Gastrointestinal Stromal Tumor Assessment by Product Type
• Gastrointestinal Stromal Tumor By Stage and Product Type
• Gastrointestinal Stromal Tumor Assessment by Route of Administration
• Gastrointestinal Stromal Tumor By Stage and Route of Administration
• Gastrointestinal Stromal Tumor Assessment by Molecule Type
• Gastrointestinal Stromal Tumor by Stage and Molecule Type

DelveInsight's Gastrointestinal Stromal Tumor Report covers around 28+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Gastrointestinal Stromal Tumor product details are provided in the report. Download the Gastrointestinal Stromal Tumor pipeline report to learn more about the emerging Gastrointestinal Stromal Tumor therapies
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Gastrointestinal Stromal Tumor Therapeutics Market include:
Key companies developing therapies for Gastrointestinal Stromal Tumor are - Novartis, Bayer, Pfizer, Deciphera Pharmaceuticals, Blueprint Medicines Corporation, Loxo Oncology, Roche, Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc., Cogent Biosciences, Inc., Plexxikon Inc., Theseus Pharmaceuticals, Exelixis, Inc., Ipsen, Bristol-Myers Squibb, Takeda, and others.

Gastrointestinal Stromal Tumor Pipeline Analysis:
The Gastrointestinal Stromal Tumor pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumor Treatment.
• Gastrointestinal Stromal Tumor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gastrointestinal Stromal Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumor market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Gastrointestinal Stromal Tumor drugs and therapies
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Gastrointestinal Stromal Tumor Pipeline Market Drivers
• Increasing prevalence of digestive disorders, increasing investment of biotechnology and pharmaceutical industries in research and development, availability of funds is likely to drive the growth of the Gastrointestinal Stromal Tumor are some of the important factors that are fueling the Gastrointestinal Stromal Tumor Market.

Gastrointestinal Stromal Tumor Pipeline Market Barriers
• However, higher cost associated with the treatment procedure and hence, this is a major fact that might be responsible for slowing the market growth, reimbursement Policies and other factors are creating obstacles in the Gastrointestinal Stromal Tumor Market growth.

Scope of Gastrointestinal Stromal Tumor Pipeline Drug Insight
• Coverage: Global
• Key Gastrointestinal Stromal Tumor Companies: IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., Cogent Biosciences, Ascentage Pharma Group, Daiichi Sankyo Company, and others
• Key Gastrointestinal Stromal Tumor Therapies: IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, PLX9486, Nilotinib, HQP1351, DS 6157, and others
• Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
• Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers

Request for Sample PDF Report for Gastrointestinal Stromal Tumor Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Gastrointestinal Stromal Tumor Report Introduction
2. Gastrointestinal Stromal Tumor Executive Summary
3. Gastrointestinal Stromal Tumor Overview
4. Gastrointestinal Stromal Tumor- Analytical Perspective In-depth Commercial Assessment
5. Gastrointestinal Stromal Tumor Pipeline Therapeutics
6. Gastrointestinal Stromal Tumor Late Stage Products (Phase II/III)
7. Gastrointestinal Stromal Tumor Mid Stage Products (Phase II)
8. Gastrointestinal Stromal Tumor Early Stage Products (Phase I)
9. Gastrointestinal Stromal Tumor Preclinical Stage Products
10. Gastrointestinal Stromal Tumor Therapeutics Assessment
11. Gastrointestinal Stromal Tumor Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Gastrointestinal Stromal Tumor Key Companies
14. Gastrointestinal Stromal Tumor Key Products
15. Gastrointestinal Stromal Tumor Unmet Needs
16 . Gastrointestinal Stromal Tumor Market Drivers and Barriers
17. Gastrointestinal Stromal Tumor Future Perspectives and Conclusion
18. Gastrointestinal Stromal Tumor Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Gastrointestinal Stromal Tumor Market https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastrointestinal Stromal Tumor-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Gastrointestinal Stromal Tumor Epidemiology https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gastrointestinal Stromal Tumor Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports Offered By DelveInsight:

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.